

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028

<https://marketpublishers.com/r/GD85161F70CEN.html>

Date: May 2022

Pages: 720

Price: US\$ 3,000.00 (Single User License)

ID: GD85161F70CEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global CAR T Cell Therapy Market & Clinical Trials Insight 2028 Report Highlights:

Research Methodology

Global CAR T Cell Therapy Market Opportunity > USD 15 Billion

Global & Regional Market Insight: Current & Market Forecast 2028

Approved CAR T Cell Therapies Sales Forecast Till 2028

Emerging In Vivo Induced CAR T Cell Therapies

CAR T Cell Therapy Manufacturing Cost Analysis

CAR T Cell Therapy Approval & Reimbursement Scenario By Country

Patent, Price, Sales Insight On 6 Approved CAR T Cell Therapies

Insight On More Than 600 CAR T Cell Therapies In Clinical Trials

CAR T Cell Therapies Clinical Trials Insights by Company, Country & Phase

Chimeric antigen receptor (CAR) T cell therapy is novel immunotherapeutic approach

which is indicated for the management of cancer. CAR T-cell therapy is a type of therapy in which the T-cells are taken from the blood of the patient, which is then modified in a lab by the addition of a gene for a man-made receptor (chimeric antigen receptor). This aids in better recognizing of specific cancer cell antigens. The CAR T-cells are then given back to the patient. To date, 6 CAR T-cell therapy products including Kymriah (tisagenlecleucel), yescarta (axicabtagene), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), and Abecma (idecabtagene vicleucel) have been approved by FDA for the management of wide range of cancers. In addition to this, Relmacabtagene autoleucel have been approved in China.

The introduction of CAR T cell therapies have shown high adoption rates in short span of time has propelled the further research and development activities in this domain. Apart from hematological malignancies, the researchers are also expanding the role of CAR T cell therapies in solid tumors which will propel the growth of market. For instance, a recent research study demonstrated that infusing immune cells into patients has shown early promise by shrinking tumors in digestive system. The interim results demonstrated that tumors in nearly 50% of the 37 patients so far reduced in size after the therapy.

The global CAR T cell therapy market is highly consolidated with several key players. The pharmaceutical giants in the market are increasingly partnering or collaborating with technologies companies to integrate advanced technologies for the betterment of CAR-T therapy or to expand geographical presence. For instance, Bayer and Atara Biotherapeutics entered into worldwide license agreement for the development of next generation ATA3271 which is mesothelin-directed CAR-T cell therapy. The agreement also aims to develop ATA2271, for the management of high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Among drug type, Yescarta is currently dominating the market. Yescarta (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma. Recently in 2022, regulatory bodies expanded the approval of drug for the management of large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within a year of first-line chemotherapy. The wide range of therapeutic indications as well as global availability of the drug is the major factors which are the major factors aiding in dominance of these factors.

As per our report findings, the Global CAR T cell therapy market opportunity is expected to surpass US\$ 15 Billion by 2028. The development of CAR T cell therapy will gather momentum from the increasing number of investors, designers, and analysts in the guide therapy. Rising frequencies of cancer across the globe together with the relentless technological advancement for dependable and effective cancer treatment is expected to support growth of the worldwide CAR-T cell therapy market. Furthermore, heavy investments on clinical research and development in cell therapy are estimated to boost the market for CAR-T cell therapy in the years to come.

Our report provides information on the globally approved CAR T cell therapies along with their price, dosage, and sales analysis. The report analyzes and forecasts the size of the global CAR-T cell therapy market. The report delivers a full-scale exploration of market dynamics and factors that are manipulating the growth of the global CAR-T cell therapy market. The report also gives competitive analysis of major market players will give a competitive advantage to customers in their respective businesses.

Contents

1. RESEARCH METHODOLOGY

2. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY - NEXT ERA IN IMMUNO ONCOLOGY

3. EVOLUTION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL DESIGN

3.1 Structure of CAR-T Cell

3.2 1st Generation Chimeric Antigen Receptor

3.3 2nd & 3rd Generation CAR-T Cell

3.4 Principle of Chimeric Antigen Receptor Design

4. APPROACHES TO IMPROVE THE EFFICACY OF CAR-T CELL THERAPY

5. CAR T CELL THERAPY MANUFACTURING COST ANALYSIS

6. EMERGING IN-VIVO INDUCED CAR T CELL THERAPIES

6.1 Need of In-Vivo CAR T Cell Therapy

6.2 In-Vivo CAR T Cell Platform; VivoVec, TumorTag, & RACR/CAR

6.3 Key Drug in Research & Development

7. GLOBAL CAR T CELL THERAPY MARKET OUTLOOK 2022 - 2028

7.1 Market Overview

7.2 Future Market Opportunity

8. GLOBALLY APPROVED CAR T CELL THERAPIES – PRICING, DOSAGE & SALES ANALYSIS 2028

8.1 Tisagenlecleucel (Kymriah)

8.2 Axicabtagene Ciloleuce (Yescarta)

8.3 Brexucabtagene Autoleucel (Tecartus)

8.4 Lisocabtagene maraleucel (Breyanzi)

8.5 Idecabtagene Vicleucel (Abecma)

8.6 Relmacabtagene autoleucel (Carteyva)

8.7 Ciltacabtagene autoleucel (Carvykti)

9. US CAR T CELL THERAPY MARKET OUTLOOK

- 9.1 Approved & Key CAR T Cell Therapy Products in US
- 9.2 Market Overview
- 9.3 Current Reimbursement Scenario

10. EUROPE CAR T CELL THERAPY MARKET OUTLOOK

- 10.1 Approved & Key CAR T Cell Therapy Products in Europe
- 10.2 UK
- 10.3 Germany
- 10.4 Spain
- 10.5 France
- 10.6 Rest of Europe
- 10.7 Current Reimbursement Scenario

11. CHINA CAR T CELL THERAPY MARKET OUTLOOK

- 11.1 Approved & Key CAR T Cell Therapy Products in China
- 11.2 Current Market Size & Forecast

12. JAPAN CAR T CELL THERAPY MARKET OUTLOOK

- 12.1 Approved & Key CAR T Cell Therapy Products in Japan
- 12.2 Market Overview
- 12.3 Current Reimbursement Scenario

13. SOUTH KOREA CAR T CELL THERAPY MARKET OUTLOOK

- 13.1 Approved & Key CAR T Cell Therapies in South Korea
- 13.2 Future Market Opportunity

14. AUSTRALIA CAR T CELL THERAPY MARKET OUTLOOK

- 14.1 Approved & Key CAR T Cell Products in Australia
- 14.2 Australia CAR T Cell Therapy Market
- 14.3 Current Reimbursement Scenario

15. TAIWAN CAR T CELL THERAPY MARKET OUTLOOK

16. GLOBAL CAR T CELLS CLINICAL PIPELINE OVERVIEW

16.1 By Company

16.2 By County

16.3 By Indication

16.4 By Phase

17. GLOBAL CAR T CELLS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

17.1 Research

17.2 Preclinical

17.3 Clinical

17.4 Phase-I

17.5 Phase-I/II

17.6 Phase-II

17.7 Phase-III

17.8 Registered

18. MARKETED CAR T CELL THERAPY CLINICAL INSIGHT

18.1 Breyanzi

18.2 CARVYKTI

18.3 Yescarta

18.4 Kymriah

18.5 Abecma

18.6 Tecartus

19. GLOBAL CAR-T CELL THERAPY MARKET DYNAMICS

19.1 Favorable Parameters

19.2 Market Challenges

20. COMPETITIVE LANDSCAPE

20.1 Autolus

20.2 Bellicum

- 20.3 Bluebird
- 20.4 Celgene
- 20.5 Collectis
- 20.6 Celyad
- 20.7 Eureka Therapeutics
- 20.8 Fortress Biotech
- 20.9 Immune Therapeutics
- 20.10 Juno Therapeutics
- 20.11 Kite Pharma
- 20.12 Novartis
- 20.13 Sorrento therapeutics
- 20.14 TILT Biotherapeutics
- 20.15 Ziopharm

List Of Figures

LIST OF FIGURES

- Figure 2-1: Historical Development of CAR-T Cell Therapy
- Figure 3-1: Structure of Chimeric Antigen Receptor
- Figure 3-2: First Generation Chimeric Antigen Receptor
- Figure 3-3: Second Generation Chimeric Antigen Receptor
- Figure 3-4: Third Generation Chimeric Antigen Receptor
- Figure 3-5: Targeting Mechanism of Chimeric Antigen Receptor T-Cell
- Figure 3-6: Signalling Mechanism of Chimeric Antigen Receptor T-Cell
- Figure 4-1: Strategies to Improve CAR T Cell Therapy
- Figure 5-1: Flowchart for Manufacturing CAR T Cells
- Figure 5-2: CAR T Cell – Annual Fixed Costs (US\$)
- Figure 5-3: CAR T Cell – Annual Fixed Costs (%)
- Figure 5-4: CAR T Cell – Variable Cost Per Production (US\$)
- Figure 5-5: CAR T Cell – Variable Cost Per Production (%)
- Figure 7-1: Global – Cancer Incidences & Deaths (Million), 2020
- Figure 7-2: Global – CAR T Cell Therapy Market by Product (US\$ Million), 2021
- Figure 7-3: Global – CAR T Cell Therapy Market by Product (%), 2021
- Figure 7-4: Global – CAR T Cell Therapy Market by Product (US\$ Million), 2020
- Figure 7-5: Global – CAR T Cell Therapy Market by Product (%), 2020
- Figure 7-6: Global – CAR T Cell Therapy Market by Region (%), 2021
- Figure 7-7: Global – CAR T Cell Therapy Market Size (US\$ Billion), 2022 - 2028
- Figure 8-1: US – Kymriah FDA Approval by Indication
- Figure 8-2: Europe – Kymriah EMA Approval by Indication
- Figure 8-3: Kymriah – Approval & Patent Exclusivity Year by Region
- Figure 8-4: UK – Per Unit Price of Kymriah Infusion Bag (GBP/US\$), May'2022
- Figure 8-5: Kymriah – Per Unit Price of Intravenous Suspension by Region (US\$), May'2022
- Figure 8-6: Global – Kymriah Annual Sales (US\$ Million), 2019 - 2021
- Figure 8-7: Global – Kymriah Quarterly Sales (US\$ Million), 2021
- Figure 8-8: Global – Kymriah Quarterly Sales (US\$ Million), 2020
- Figure 8-9: Global – Kymriah Sales Forecast Value (US\$ Million), 2022 - 2028
- Figure 8-10: US – Yescarta FDA Approval by Indication
- Figure 8-11: Yescarta - Approval Year by Region
- Figure 8-12: US – Yescarta FDA Approval & Patent Expiration Year
- Figure 8-13: UK – Per Unit Price of Yescarta Infusion Bag (GBP/US\$), May'2022
- Figure 8-14: Yescarta – Per Unit Price of Intravenous Suspension by Region (US\$),

May'2022

Figure 8-15: Yescarta – Global Sales by Region (US\$ Million), Q1'2022

Figure 8-16: Yescarta – Global Sales by Region (%), Q1'2022

Figure 8-17: Global – Yescarta Annual Sales (US\$ Million), 2018 - 2021

Figure 8-18: US – Yescarta Annual Sales (US\$ Million), 2018 - 2021

Figure 8-19: Yescarta – Global Sales by Region (US\$ Million), 2021

Figure 8-20: Yescarta – Global Sales by Region (%), 2021

Figure 8-21: Global – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-22: US – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-23: Europe – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-24: Global – Yescarta Quarterly Sales (US\$ Million), 2020

Figure 8-25: Global – Yescarta Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-26: US – Yescarta Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-27: Europe – Yescarta Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-28: US – Tecartus FDA Approval by Indication

Figure 8-29: UK – Per Unit Price of Tecartus Infusion Bag (GBP/US\$), May'2022

Figure 8-30: Tecartus – Per Unit Price of Intravenous Suspension by Region (US\$),
May'2022

Figure 8-31: Tecartus – Global Sales by Region (US\$ Million), Q1'2022

Figure 8-32: Tecartus – Global Sale by Region (%), Q1'2022

Figure 8-33: Global – Tecartus Annual Sales (US\$ Million), 2020 & 2021

Figure 8-34: US – Tecartus Annual Sales (US\$ Million), 2020 & 2021

Figure 8-35: Tecartus – Global Sales by Region (US\$ Million), 2021

Figure 8-36: Tecartus – Global Sales by Region (%), 2021

Figure 8-37: Global – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-38: US – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-39: Europe – Yescarta Quarterly Sales (US\$ Million), 2021

Figure 8-40: Global – Tecartus Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-41: US – Tecartus Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-42: Breyanzi - Approval Year by Region

Figure 8-43: Breyanzi – Global Sales by Region (US\$ Million), Q1'2022

Figure 8-44: Breyanzi – Global Sales by Region (%),Q1'2022

Figure 8-45: Global – Breyanzi Quarterly Sales (US\$ Million), Q2-Q4'2021

Figure 8-46: Global – Breyanzi Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-47: US – Breyanzi Sales Forecast (US\$ Million), 2022 - 2028

Figure 8-48: Abecma - Approval Year by Region

Figure 8-49: Abecma – Global Sales by Region (US\$ Million), Q1'2022

Figure 8-50: Abecma – Global Sales by Region (%),Q1'2022

Figure 8-51: Abecma – Global Sales by Region (US\$ Million), 2021

- Figure 8-52: Abecma – Global Sales by Region (%), 2021
- Figure 8-53: Global – Abecma Quarterly Sales (US\$ Million), Q2-Q4'2021
- Figure 8-54: US – Abecma Quarterly Sales (US\$ Million), Q2-Q4'2021
- Figure 8-55: Global – Abecma Sales Forecast (US\$ Million), 2022 - 2028
- Figure 8-56: US – Abecma Sales Forecast (US\$ Million), 2022 - 2028
- Figure 8-57: China – Carteyva Sales Forecast (US\$ Million), 2022 - 2028
- Figure 8-58: Global – Carvykti Sales Forecast (US\$ Million), 2022 - 2028
- Figure 9-1: US – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 9-2: US vs. ROW – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 9-3: US vs. ROW – CAR T Cell Therapy Market Size (%), 2021
- Figure 9-4: US – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 9-5: US – Cost of Drug & Total Cost of Treatment with CAR T Cell Therapy (US\$), 2021
- Figure 9-6: US – Cost of Single Infusion & Reimbursement Cost for Abecma & Breyanzi (US\$)
- Figure 9-7: US – Out of Pocket Cost & Reimbursement Cost for Abecma & Breyanzi (%)
- Figure 10-1: UK – Cancer Incidences & Deaths, 2020 & 2025
- Figure 10-2: UK vs. ROE – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 10-3: UK vs. ROE – CAR T Cell Therapy Market Size (%), 2021
- Figure 10-4: UK – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 10-5: Germany – Cancer Incidences & Deaths, 2020 & 2025
- Figure 10-6: Germany vs. ROE – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 10-7: Germany vs. ROE – CAR T Cell Therapy Market Size (%), 2021
- Figure 10-8: Germany – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 10-9: Spain – Cancer Incidences & Deaths, 2020 & 2025
- Figure 10-10: Spain vs. ROE – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 10-11: Spain vs. ROE – CAR T Cell Therapy Market Size (%), 2021
- Figure 10-12: Spain – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 10-13: France – Cancer Incidences & Deaths, 2020 & 2025
- Figure 10-14: France vs. ROE – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 10-15: France vs. ROE – CAR T Cell Therapy Market Size (%), 2021
- Figure 10-16: France – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 10-17: Europe – Cancer Incidences & Deaths (Million), 2020 & 2025
- Figure 10-18: Europe vs. ROW – CAR T Cell Therapy Market Size (US\$ Million), 2021
- Figure 10-19: Europe vs. ROW – CAR T Cell Therapy Market Size (%), 2021
- Figure 10-20: Rest of Europe – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028
- Figure 10-21: UK – Average Cost of Reimbursement with Kymriah & Yescarta per QALY (Euro/US\$)

Figure 11-1: China – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 11-2: China – CAR T Clinical Trials by Phase'2020

Figure 11-3: China – Top 5 Pharmaceutical Companies Supporting CAR T Clinical Trials'2021

Figure 11-4: China – CAR T Cell Therapy Market Size (US\$ Million), 2021 – 2028

Figure 12-1: Japan – Cancer Incidences & Deaths (Million), 2020 & 2025

Figure 12-2: Japan vs. ROW – CAR T Cell Therapy Market Size (US\$ Million), 2021

Figure 12-3: Japan vs. ROW – CAR T Cell Therapy Market Size (%), 2021

Figure 12-4: Japan – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028

Figure 12-5: Japan – Current Retail & Reimbursed Price for Kymriah (JPY/US\$), 2021

Figure 13-1: South Korea – Cancer Incidences & Deaths, 2020 & 2025

Figure 13-2: South Korea – CAR T Cell Therapy Market Size (US\$ Million), 2021 – 2028

Figure 14-1: Australia – Cancer Incidences & Deaths, 2020 & 2025

Figure 14-2: Australia vs. ROW – CAR T Cell Therapy Market Size (US\$ Million), 2021

Figure 14-3: Australia vs. ROW – CAR T Cell Therapy Market Size (%), 2021

Figure 14-4: Australia – CAR T Cell Therapy Market Size (US\$ Million), 2022 – 2028

Figure 15-1: Taiwan – CAR T Cell Therapy Market Size (US\$ Million), 2021 – 2028

Figure 16-1: Global - CAR T Cells Clinical Pipeline by Company, 2022 till 2028

Figure 16-2: Global - CAR T Cells Clinical Pipeline by Country, 2022 till 2028

Figure 16-3: Global - CAR T Cells Clinical Pipeline by Indication, 2022 till 2028

Figure 16-4: Global - CAR T Cells Clinical Pipeline by Phase, 2022 till 2028

Figure 19-1: Favorable Market Parameters of CAR T Cell Therapy

Figure 19-2: Challenges to Market Growth of CAR T Cell Therapy

List Of Tables

LIST OF TABLES

Table 3-1: Antigens which are targeted by Chimeric Antigen Receptor

Table 5-1: CAR T Cell – Per Production Cost (US\$)

Table 6-1: Advantage of VivoVec Platform over Traditional Platform

Table 6-2: ENLIGHTen – Phase I Trial Initiation & Completion Year

Table 9-1: US – FDA Approved CAR T Cell Therapy Products

Table 10-1: Europe – Approved CAR T Cell Therapy Products

Table 12-1: Japan – MHLW Approved CAR T Cell Therapy Products

Table 14-1: Australia –Approved CAR T Cell Therapy Products

Table 20-1: Clinical Pipelines of Products

I would like to order

Product name: Global CAR T Cell Therapy Market & Clinical Trials Insight 2028

Product link: <https://marketpublishers.com/r/GD85161F70CEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD85161F70CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970